Compare FNWB & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | ACET |
|---|---|---|
| Founded | 1923 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 93.5M |
| IPO Year | 2015 | N/A |
| Metric | FNWB | ACET |
|---|---|---|
| Price | $9.98 | $0.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.50 | $8.50 |
| AVG Volume (30 Days) | 31.1K | ★ 2.3M |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,052,000.00 | N/A |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $6.05 | $0.45 |
| 52 Week High | $12.10 | $1.11 |
| Indicator | FNWB | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 33.12 |
| Support Level | $9.80 | $0.50 |
| Resistance Level | $10.14 | $0.59 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 53.85 | 4.30 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.